No Data
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $42
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $37 to $75
Beam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy Rating
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
